Our Management Team

John Husnik, Ph.D. Founder, Director, and CEO

Dr. John Husnik is a leading researcher in the area of yeast strain development techniques, as well as having significant experience developing and applying novel and innovative yeast-based solutions to multiple food and beverage industry problems. Over the past five years, John and his team have worked tirelessly to advance the H2S-preventing wine yeast traits originally discovered and patented by Dr. Linda Bisson at the University of California, Davis. In addition, John and his team discovered, patented and are commercializing the acrylamide-reducing yeast technology owned by Renaissance BioScience Corp. + More

Maurice Boucher Founder, Chairman, and CFO

Maurice Boucher has more than 28 years experience in the financial community, most of which has been concentrated in the equity funding and financial market development of early-stage technology companies. He holds a Bachelor of Commerce degree from the University of British Columbia, majoring in Finance and Accounting and he articled in tax, accounting, and audit with the small business division of Price Waterhouse in Vancouver, Canada. His finance career started in the retail brokerage industry, advancing to VP, Corporate Finance, Venture Capital, for the Hong Kong division of Standard Chartered Bank. + More

Cormac O’Cleirigh, Ph.D. Chief Business Development Officer

A native of Ireland with a Ph.D in Bioprocess Engineering, Dr. O’Cleirigh has extensive experience and expertise at the senior executive level in the global yeast and bakery ingredient industry. Prior to joining Renaissance, Dr. O’Cleirigh was Head of Business Development & Innovation for AB Mauri Global Bakery Ingredients, a division of FTSE 100 listed Associated British Foods plc. In this role, his primary responsibilities included overseeing the division’s strategic business development, with a focus on developing consumer insights, evaluating competitor intelligence, and identifying acquisition targets. Other key responsibilities included coordinating the company’s global innovation team and managing the business’s innovation systems and processes. + More

Doug Janzen Director

Doug Janzen has been involved in the life sciences industry for the past 19 years. He is currently the founder and President of NorthView Ventures, an entity which invests in and provides strategic advisory services to a number of technology companies. Prior to that, he was President and CEO of Cardiome Pharma Corp., a NASDAQ-listed drug development company which raised over $300 million from investors and completed over $1 billion in licensing deals during his tenure. + More

Steven Palmer Director

Steven is a founding partner and Chief Investment Officer of AlphaNorth Asset Management. Prior to founding AlphaNorth in 2007, from 1998 to 2007 he was employed at one of the world's largest financial institutions as Vice President - Canadian Equities where he managed the Canadian equity assets of approximately $350 million and a number one ranked pooled fund which focused on Canadian small capitalization companies. + More